Obezite ve COVID-19

Beda Özalp; Nilgün Seremet Kürklü

Obezite ve COVID-19

Abstract

Özet

Şiddetli Akut Solunum Sendromu Koronavirüs-2 (SARS-CoV-2), Dünya Sağlık Örgütü (DSÖ) tarafından Koronavirus Hastalığı 2019 (COVID-19) olarak adlandırılan hastalığın etkeni olan yeni tip koronavirüstür. İlk olarak Çin’in Wuhan şehrinde ortaya çıkmış ve tüm dünyaya hızla yayılmıştır. İnsandan insana çok hızlı bulaşabilen COVID-19, yaş ile ilişkili olmakla birlikte hipertansiyon, diyabet, kardiyovasküler hastalıklar vb. komorbiditesi olan bireylerde daha şiddetli seyretmektedir. Günümüzün önemli bir halk sağlığı sorunu olan obezite; bulaşıcı olmayan kronik hastalıkların oluşma riskini arttırmakta ve solunum yolu hastalıklarının gelişmesine neden olmaktadır. Obezite ile COVID-19 arasındaki ilişkiyi ortaya koyacak mekanizma net olarak bilinmemesine rağmen yapılan çalışmalarla, vücut ağırlığındaki artışın COVID-19 enfeksiyonu şiddetini de arttığını gösterilmiştir. Sonuç olarak tüm dünyada ve ülkemizde önemli bir sağlık sorunu olan COVID-19 hastalığının tedavisinde; diyabet, hipertansiyon vb hastalıkların yanı sıra hastalığın seyrinin hafifletilmesi ve yoğun bakımdaki hasta sayısının ve kalış süresinin azaltılması amacıyla obeziteye de dikkat edilmesi gerekmektedir. Bu derlemede obezite ve COVID-19 arasındaki ilişki ve olası mekanizmalar tartışılmıştır.

Anahtar Kelimeler: Obezite, beden kütle indeksi, COVID-19, inflamasyon.

Abstract

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), a new type of coronavirus which is the cause of disease named the Coronavirus Disease 2019 (COVID-19) by the World Health Organization (WHO), first appeared in Wuhan, China and spread all over the world rapidly. COVID-19, which can be transmitted rapidly from person to person, is age-related; however, it is more severe in people with comorbidities such as hypertension, diabetes, cardiovascular disease, etc. Being one of the serious health issues today, obesity increases the risk of non-communicable diseases and causes the development of respiratory diseases. Although the mechanism between obesity and COVID-19 is not clearly known, studies have shown that the increase in body weight is positively associated with the severity of COVID-19 infection, the need for treatment in the intensive care unit, and the rates of mechanical ventilation. Consequently, obesity should be considered in the prevention and treatment of COVID-19 disease, which is a critical health issue across the world and in our country, in addition to chronic diseases, to reduce the course of the disease and complications. In this study, the relationship and possible mechanisms between obesity and COVID-19 are discussed.

Keywords: Obesity, body mass index, COVID-19, inflammation.

Keywords

References

Bornstein, S. R., Dalan, R., Hopkins, D., Mingrone, G., Boehm, B. O. (2020). Endocrine and metabolic link to coronavirus infection. Nature Reviews Endocrinology, 16(6), 297–298.
Cai, Q., Chen, F., Wang, T., Luo, F., Liu, X., Wu, Q. (2020b). Obesity and COVID-19 severity in a designated hospital in shenzhen, China. Preprints with The Lancet. https://papers.ssrn.com/sol3/papers. cfm?abstract_id=3556658&fbclid=IwAR1d8yXcTO6l7lgAbw_ eSidmXdtmtJyVLXWr3NuTL3G9FwkODpFrkKeeO40.
Cai, Q., Huang, D., Ou, P., Yu, H., Zhu, Z., Xia, Z., et al. (2020a). COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. Allergy, doi.org/10.1111/all.14309
Caspard, H., Jabbour, S., Hammar, N., Fenici, P., Sheehan, J. J., Kosiborod, M. (2018). Recent trends in the prevalence of type 2 diabetes and the association with abdominal obesity lead to growing health disparities in the USA: An analysis of the NHANES surveys from 1999 to 2014. Diabetes, Obesity and Metabolism, 20(3), 667‐671.
De Rosa, V., Procaccini, C., La Cava, A., Chieffi, P., Nicoletti, G. F., Fontana, S., et al. (2006). Leptin neutralization interferes with pathogenic T cell autoreactivity in autoimmune encephalomyelitis. The Journal of Clinical Investigation, 116(2), 447–455.
FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic. Retrieved May 10. 2020, http://www.klinikarastirmalar.org/upload/documents/Clinical-Trial-Conductduring- COVID-19-Direct-to-Final-3-17-20.pdf.
Green, W. D., & Beck, M. A. (2017). Obesity Impairs the Adaptive Immune Response to Influenza Virus. Annals of the American Thoracic Society, 14(5), 406–409.
Iacobellis, G. (2020). COVID-19 and diabetes: Can DPP4 inhibition play a role?. Diabetes Research and Clinical Practice, 162, 108125.

Kılıç, T. (2010). Obezite ile iliskili oksidatif stresin altinda yatan mekanizmalar: Leptin ve adiponektinin rolü. Anadolu Kardiyoloji Dergisi, 10(5), 397-9.
Lighter, J., Phillips, M., Hochman, S., Sterling, S., Johnson, D., Francois, F., et al. (2020). Obesity in patients younger than 60 years is a risk factor for COVID-19 hospital admission. Clinical İnfectious Diseases:An Official Publication of The Infectious Diseases Society of America, ciaa415.
Mahase E. (2020). COVID-19: most patients require mechanical ventilation in first 24 hours of critical care. British Medical Journal (Clinical research ed.), 368, m1201.
Morgan, O. W., Bramley, A., Fowlkes, A., Freedman, D.S., Taylor, T. H., Gargiullo, P., et al. (2010). Morbid obesity as a risk factor for hospitalization and death due to 2009 pandemic influenza A(H1N1) disease. PloS One, 5(3), e9694.
O’Hara, A. M., & Shanahan, F. (2006). The gut flora as a forgotten organ. European Molecular Biology Organization Reports, 7(7), 688–693.
Özbalcı, D., Şahin, M. (2009). Leptin ve immün sistem. Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi, 14 (2) , 51-55
Petrakis, D., Margină, D., Tsarouhas, K., Tekos, F., Stan, M., Nikitovic, D., et al. (2020). Obesity ‑ a risk factor for increased COVID‑19 prevalence, severity and lethality (Review). Molecular Medicine Reports, 22(1), 9-19.
Petrilli, C. M., Jones, S. A., Yang, J., O’Donnell, L. F., Chernyak, Y., Tobin, K., et al. (2020). Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City. British Medical Journal, 369, m1966.
Simonnet, A., Chetboun, M., Poissy, J., Raverdy, V., Noulette, J., Duhamel, A., et al. (2020). High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring), 10.1002/ oby.22831.
Sohrabi, C., Alsafi, Z., O’Neill, N., Khan, M., Kerwan, A., Al-Jabir, A., et al. (2020). World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). International Journal of Surgery (London, England), 76, 71–76.
Sun, Y., Wang, Q., Yang, G., Lin, C., Zhang, Y., Yang, P. (2016). Weight and prognosis for influenza A(H1N1)pdm09 infection during the pandemic period between 2009 and 2011: a systematic review of observational studies with meta-analysis. Infectious Diseases (London, England), 48(11-12), 813–822.
Tekin, T., Çiçek, B., Konyalıgil, N. (2018). İntestinal mikrobiyota ve obezite ilişkisi. Sağlık Bilimleri Dergisi, 27(1) , 95-99.
Türkiye Beslenme ve Sağlık Araştırması 2010 (TBSA) (2014). https:// hsgm.saglik.gov.tr/depo/birimler/saglikli-beslenme-hareketlihayat- db/Yayinlar/kitaplar/diger-kitaplar/TBSA-Beslenme-Yayini. pdf. Erişim Tarihi: 11.05.2020.
Wang, B. & Trayhurn, P. (2006). Acute and prolonged effects of TNFalpha on the expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture. European Journal of Physiology, 452(4), 418–427.
WHO/FAO. Diet, nutrition and the prevention of chronic diseases. WHO, Geneva, 2003. Retrieved April 20. 2020, https://www.who. int/dietphysicalactivity/publications/trs916/en/.
World Health Organization (WHO). Obesity and Overweight Fact Sheet No:311, updated. Geneva; 2018. Retrived April 15. 2020, http:// www.who.int/mediacentre/factsheets/fs311/en/.
Zheng, K. I., Gao, F., Wang, X. B., Sun, Q. F., Pan, K. H., Wang, T. Y., et al. (2020). Obesity Is a Risk Factor for Greater COVID-19 Severity. Diabetes Care, 2020.

Details

Primary Language

Turkish

Subjects

Health Care Administration

Journal Section

Review

Authors

Beda Özalp
0000-0002-7923-842X
Türkiye

Nilgün Seremet Kürklü ^*
0000-0003-1394-0037
Türkiye

Publication Date

June 30, 2020

Submission Date

June 5, 2020

Acceptance Date

June 5, 2020

Published in Issue

Year 2020 Volume: 5 Number: 2

IZ

https://izlik.org/JA23JG58YF

Cite

RIS / Bibtex

APA

Özalp, B., & Seremet Kürklü, N. (2020). Obezite ve COVID-19. İzmir Katip Çelebi Üniversitesi Sağlık Bilimleri Fakültesi Dergisi, 5(2), 211-214. https://izlik.org/JA23JG58YF

AMA

1.Özalp B, Seremet Kürklü N. Obezite ve COVID-19. İKÇÜSBFD. 2020;5(2):211-214. https://izlik.org/JA23JG58YF

Chicago

Özalp, Beda, and Nilgün Seremet Kürklü. 2020. “Obezite Ve COVID-19”. İzmir Katip Çelebi Üniversitesi Sağlık Bilimleri Fakültesi Dergisi 5 (2): 211-14. https://izlik.org/JA23JG58YF.

EndNote

Özalp B, Seremet Kürklü N (June 1, 2020) Obezite ve COVID-19. İzmir Katip Çelebi Üniversitesi Sağlık Bilimleri Fakültesi Dergisi 5 2 211–214.

IEEE

[1]B. Özalp and N. Seremet Kürklü, “Obezite ve COVID-19”, İKÇÜSBFD, vol. 5, no. 2, pp. 211–214, June 2020, [Online]. Available: https://izlik.org/JA23JG58YF

ISNAD

Özalp, Beda - Seremet Kürklü, Nilgün. “Obezite Ve COVID-19”. İzmir Katip Çelebi Üniversitesi Sağlık Bilimleri Fakültesi Dergisi 5/2 (June 1, 2020): 211-214. https://izlik.org/JA23JG58YF.

JAMA

1.Özalp B, Seremet Kürklü N. Obezite ve COVID-19. İKÇÜSBFD. 2020;5:211–214.

MLA

Özalp, Beda, and Nilgün Seremet Kürklü. “Obezite Ve COVID-19”. İzmir Katip Çelebi Üniversitesi Sağlık Bilimleri Fakültesi Dergisi, vol. 5, no. 2, June 2020, pp. 211-4, https://izlik.org/JA23JG58YF.

Vancouver

1.Beda Özalp, Nilgün Seremet Kürklü. Obezite ve COVID-19. İKÇÜSBFD [Internet]. 2020 Jun. 1;5(2):211-4. Available from: https://izlik.org/JA23JG58YF